Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway

Copyright © 2021 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 227(2021) vom: 09. Juni, Seite 108728
1. Verfasser: Chen, Ying (VerfasserIn)
Weitere Verfasser: Li, Fangxuan, Li, Dan, Liu, Wenxin, Zhang, Lei
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Long non-coding RNA Ovarian cancer PD-L1 PVT1 Resistant Antibodies, Monoclonal, Humanized Antineoplastic Agents B7-H1 Antigen Immune Checkpoint Inhibitors mehr... PVT1 long-non-coding RNA, human RNA, Long Noncoding RNA, Small Interfering STAT3 Transcription Factor atezolizumab 52CMI0WC3Y Janus Kinase 2 EC 2.7.10.2 Cisplatin Q20Q21Q62J
Beschreibung
Zusammenfassung:Copyright © 2021 Elsevier Inc. All rights reserved.
OBJECTIVE: To investigate the relationship between lncRNA PVT1(PVT1) level and PD-L1 expression and their functions in cisplatin resistant epithelial ovarian cancer (CREOC)
METHODS: PVT1 and PD-L1 in ovarian cancer tissues were detected and analyzed. The cells proliferation, apoptosis, invasion abilities and potential mechanism were detected by cell functional experiments and western-blot assay, respectively
RESULTS: The average expressions of PVT1 and PD-L1 in CREOC tissues were significantly higher. The expression of PVT1 is positively associated with PD-L1 in CREOC. Higher expressions of PVT1 and PD-L1 indicated more malignant clinical behavior and shorter PFS and OS. Knockdown of PVT1 inhibited the proliferation and invasion and promote apoptosis for A2780cis cells, which may be related to decrease the expression of PD-L1 via repressing JAK2/STAT3 pathway
CONCLUSIONS: The synergistic therapeutic strategy using LncRNA PVT1-targeted therapy and immune checkpoint blockade of PD-L1 warrant study further for ovarian cancer patients with cisplatin resistant recurrence
Beschreibung:Date Completed 26.07.2021
Date Revised 26.07.2021
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2021.108728